The Catalyst

Most Recent Posts


In a blog post today, Pharmalot delves into various opinions on biopharmaceutical research and development (R&D) spending.


Today we're featuring a blog post from Val Halamandaris, the President of the National Association for Home Care and Hospice (NAHC).

09.07.12 | By Mark Grayson

With the start of the next round of negotiations for the Trans Pacific Partnership in Leesburg, Virginia many Americans probably do not know how important these talks are to U.S. jobs and exports. The biopharmaceutical sector directly employed more than 650,000 U.S. workers in 2009, supporting a total of 4 million jobs [in areas such as construction, trucking, and information technology.

09.07.12 | By John Castellani

The clock is ticking as we count down the remaining days until the first ever Research and Hope Award ceremony, where we will have the privilege of honoring individuals who have made incredible sacrifices in the great battle against Alz


Ten thousand baby boomers will turn 65 today. This will happen again tomorrow, the next day and every day until 2030. With such a significant growth in Medicare eligible Americans, ensuring effective coverage and access to medicines well into the future is a priority.


Yet more proof of the value of exercise - at every age.


As part of our "From Hope to Cures" guest blog series, below is a post from the Alzheimer's Foundation of America President and CEO, Eric J. Hall, on the significant research and progress that will help lead to innovative treatments.


My first anniversary as a PhRMA road warrior traveling from state to state to help educate legislators, health policymakers, reporters and others about industry clinical trials of new medicines is rapidly approaching.


A strong U.S. biopharma industry is vital to ensuring the health of our nation's economy and citizens. Investment in R&D supports jobs within a variety of U.S. industries. The below infographic explains how only with a strong and growing biopharma sector can we add jobs, reduce long term healthcare costs and prolong the quality of life for all Americans.


Erin Mullen wrote a great post about lessons learned in Hurricane Andrew, and stopped by my office yesterday to talk about what's been going on with Rx Response in light of Hurricane Isaac this week.


I've read many interesting blog posts by John LaMattina, formerly the president of Pfizer R&D, but today's post a


For nearly 30 years, PhRMA has held an annual awards event called the Discoverer's Award to honor pioneers in the biopharmaceutical industry whose discoveries helped move the goal post forward in the war against disease. Past recipients were honored for discovering breakthrough medicines for diseases such as cervical cancer, depression, diabetes and HIV/AIDS.

08.27.12 | By Scott LaGanga

Earlier this month, I traveled to China to meet with public and private sector officials working to address the global counterfeit drug epidemic.


Yesterday, I highlighted a nice video produced by PhRMA on the prescription drug life cycle. Today, I'd like to talk a bit more about the prescription drug life cycle concept portrayed in that video - a concept with which many people are unfamiliar.


If you haven't had a chance to see Eli Lilly's CEO Dr. John Lechleiter speak, I strongly encourage it. Dr. Lechleiter is a wonky, funny and brilliant former chemist who is a passionate stalwart on the issue of counterfeit drugs.